Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18670642 | 1.00 | PRKCA (0.41) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL29678666 | 0.89 | PRKCA (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL29429746 | 0.81 | POLB (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL31308611 | 0.81 | POLB (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670630 | 0.80 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670654 | 0.80 | HPGD (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL26123656 | 0.80 | PRKCG (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL26123217 | 0.80 | PRKCG (0.40) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670646 | 0.79 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD | |
| SCHEMBL18670648 | 0.79 | SCN1A (0.38) | PRKCAPRKCGPRKCBPRKCEPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250136603-A1 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | GILEAD SCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-108289931-B | 4' -substituted nucleoside reverse transcriptase inhibitors and preparation thereof | 默沙东公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-05-27 | — | — | US | disclosed |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3352781-B1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20190185508-A1 | DEUTERATED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3352781-A2 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | Merck Sharp & Dohme Corp. (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017053216-A2 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154221-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, SAMHD1, DUT | PRKCA 4168/4885PRKCG 4177/4885PRKCB 4191/4885 |
| US-20190185508-A1 | DEUTERATED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, DIMT1, POLRMT | PRKCA 4441/4885PRKCG 4366/4885PRKCB 4448/4885 |
| US-20250136603-A1 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | PNP, MTAP, TYMP | PRKCA 4171/4885PRKCG 4338/4885PRKCB 4220/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | PRKCA 2192/4885PRKCG 2090/4885PRKCB 2176/4885 |
| US-20190022115-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | HPRT1, DUT, SAMHD1 | PRKCA 4291/4885PRKCG 4261/4885PRKCB 4305/4885 |
| US-10953029-B2 | 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof | DUT, HPRT1, SAMHD1 | PRKCA 4246/4885PRKCG 4221/4885PRKCB 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.